May 2026 - The cell therapy industry is entering a new phase of commercialization as companies increasingly focus on scalable and automated manufacturing infrastructure. This week, Cabaletta Bio and C...
On April 21, a South Korean business delegation visited Wuzhong District, where the Wuzhong District People’s Government and the Korea Bio-Pharma Association jointly organized a China-South Korea Bus...
April 2026 - Eli Lilly and Company has announced plans to acquire biotechnology firm Kelonia Therapeutics in a deal valued at up to $7 billion, highlighting the growing strategic importance of next-ge...
April 2026 - Researchers are continuing to uncover new biological targets that could expand the potential of engineered immune cell therapies. Recently, Precision Biologics reported the identification...
April 2026 - Researchers and biotechnology companies continue to expand the potential of natural killer (NK) cell therapies as new targets and engineering strategies emerge. Recently, Precision Biolog...
April 2026 - The clinical development of CAR-NK cell therapies may be entering a new phase as treatment logistics become simpler and more accessible. Recently, Nkarta announced that it has reached an ...
April 2026 - Recent policy discussions in the United States are raising new questions for the global biopharmaceutical industry. The administration of Donald Trump is reportedly considering tariffs on...
April 2026 - Recent advances in NK cell manufacturing are drawing renewed attention to one of the most critical challenges in cell therapy development: scalable and efficient cell expansion. A newly r...
On February 24, 2026, the National Health Commission of China (NHC) released an official interpretation of Order No. 818 – Regulation on the Management of Clinical Research and Translational Applicat...
April 2026 - Recent clinical findings highlight the growing potential of CAR-NK cell therapy in the treatment of hematologic malignancies. A study reported that a CD19-targeted CAR-NK therapy achie...
March 27, 2026 - The global immuno-oncology field is witnessing a significant milestone: several CAR‑NK (chimeric antigen receptor natural killer) cell therapy programs have now entered first-in-huma...
If CAR-T therapy is the “star” of the immunotherapy field, then natural killer (NK) cell therapy is poised to become the next “top trend.” With its three core advantages—readiness for use, safety...
86 198 5711 6962 
info@hillgene.com 
English
